List view / Grid view
22 September 2015 | By Victoria White
The companies have applied a crowdsourcing approach to establish a research team who will endeavour to identify new approaches for the treatment of patients with COPD...
1 September 2015 | By Nick Jackson
Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation...
22 May 2015 | By Victoria White
Eureka Therapeutics and Boehringer Ingelheim have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology...
14 April 2015 | By Victoria White
Hydra Biosciences and Boehringer Ingelheim have entered into a research collaboration with a primary focus on the treatment of renal diseases and disorders...
19 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, jointly announce an exclusive global license and development collaboration...
4 August 2014 | By Boehringer Ingelheim & Zealand Pharma
Zealand Pharma and Boehringer Ingelheim jointly announced a new global exclusive licence, research and development collaboration...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
12 May 2014 | By Boehringer Ingelheim
In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program...
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...
